Telix在巴塞罗那的2025年EANM大会上提供了最新的癌症试验数据和新的成像技术。 Telix presents latest cancer trial data and new imaging tech at 2025 EANM Congress in Barcelona.

Telix制药公司在巴塞罗那举行的2025年EANM大会上提交了28份摘要,这是其最大的一次展示,突出介绍了前列腺癌TLX591试验阶段3的数据、古洛玛TLX101治疗试验以及肾癌TLX250-CDx实际结果。 Telix Pharmaceuticals is presenting 28 abstracts at the 2025 EANM Congress in Barcelona, its largest show yet, highlighting Phase 3 trial data for TLX591 in prostate cancer, therapeutic trials of TLX101 in glioma, and real-world results for TLX250-CDx in kidney cancer. 该公司还在展示新型放射药品、AI驱动成像工具、综合疗法以及Illuccix、SENSEI和QDOSE等医疗技术。 The company is also showcasing new radiopharmaceuticals, AI-driven imaging tools, combination therapies, and medical technologies like Illuccix, SENSEI, and QDOSE. 欧洲和国际专家将参加关于以FAP和CAIX为对象的专题讨论会,Telix则通过Sanjiv Sam Gambhir奖继续支持青年研究人员。 A symposium on FAP and CAIX targeting will feature European and international experts, while Telix continues supporting young researchers through the Sanjiv Sam Gambhir Award. 这场活动持续10月4日至8日。 The event runs October 4–8.